Related Experiment Video
Updated: Jan 18, 2026
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Exosomal miR-320c: A Novel Biomarker for Atrial Cardiomyopathy
Yangcheng Xue1, Zhuoran Jia1, Shichu Liang2
1Department of Cardiology, First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, 230022, Anhui, China.
Insights
Early diagnosis of atrial cardiomyopathy (ACM) in atrial fibrillation (AF) patients is vital. Exosomal miR-320c shows potential as a biomarker for severe left atrial fibrosis, aiding early detection and treatment.
Area of Science:
- Cardiology
- Biomarkers
- Molecular Biology
Background:
- Atrial cardiomyopathy (ACM) diagnosis and treatment are critical for atrial fibrillation (AF) patients.
- Identifying reliable biomarkers for ACM, especially in cases of left atrial fibrosis, is essential for improved patient outcomes.
- Current diagnostic methods require further refinement, necessitating exploration of novel molecular markers.
Purpose of the Study:
- To identify novel exosomal microRNAs (miRNAs) as potential biomarkers for severe left atrial fibrosis in patients with persistent atrial fibrillation (PeAF).
- To investigate the differential expression of exosomal miRNAs in patients with varying degrees of left atrial fibrosis and supraventricular tachycardia (SVT).
- To evaluate the potential of identified exosomal miRNAs as diagnostic markers and therapeutic targets for ACM.
Main Methods:
- High-throughput sequencing of exosomal miRNAs from blood samples of patients with persistent AF (PeAF) and SVT.
- Validation of differentially expressed miRNAs (DE miRNAs) using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR).
- Bioinformatic analyses including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) for target gene identification.
Main Results:
- Four exosomal DE miRNAs were identified: miR-5106, let-7e-5p, miR-320c, and miR-382-3p.
- Exosomal miR-320c was significantly down-regulated in patients with severe left atrial fibrosis and PeAF compared to controls.
- No significant expression changes were observed for miR-5106, let-7e-5p, and miR-382-3p in the severe fibrosis group.
Conclusions:
- Exosomal miR-320c is a promising candidate biomarker for the early detection of severe left atrial fibrosis in ACM patients.
- The findings suggest that exosomal miR-320c could serve as a valuable diagnostic tool and a potential therapeutic target for ACM.
- Further research is warranted to elucidate the functional role of miR-320c in the pathogenesis of atrial fibrosis and ACM.
Abstract:
Early diagnosis and treatment of atrial cardiomyopathy(ACM) are crucial for patients with atrial fibrillation(AF), and further exploration of its biomarkers remains necessary. High-throughput sequencing of exosomal miRNAs was performed on blood samples from patients with persistent AF (PeAF) exhibiting mild and severe left atrial fibrosis, with supraventricular tachycardia (SVT) patients. Quantitative real-time reverse transcription polymerase chain reaction analysis validated differentially expressed miRNAs (DE miRNAs) from severe left atrial fibrosis PeAF, SVT and health controls. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were conducted on target genes. Four exosomal DE miRNAs were identified, including miR-5106, let-7e-5p, miR-320c, and miR-382-3p. Exosomal miR-320c was down-regulated in severe left atrial fibrosis PeAF patients, while the other three miRNAs showed no significant changes. Exosomal miR-320c emerges as a potential biomarker for severe left atrial fibrosis and ACM, suggesting its suitability as a therapeutic target.
More Related Videos
09:16Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
Published on: February 28, 2018
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
